The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

This cancer treatment stock is nearing a buy point of a base after quarterly earnings. The Eli Lilly partner reports positive ...

Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent ...

Eli Lilly is poised to become the first $1 trillion pharmaceutical company, driven by explosive growth in its weight-loss ...

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

Eli Lilly (LLY) stock is trading at record highs after the pharmaceutical company reached a deal with the White House to ...

In today’s Pharmaceutical Executive Daily learn how Novo Nordisk is restructuring leadership to enhance scientific and commercial alignment, ABL Bio secures a major multi-program partnership with Eli ...

The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.

Berkshire Hathaway's diversification, culture, and investment philosophy should still make it a great long-term buy, but ...

The Trump administration is negotiating an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some ...

Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...